VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Cereblon and GSPT1 degrader in refractory/relapsed AML

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, outlines the Phase I, dose-escalation and expansion, first-in-human clinical study (NCT02848001) of CC-90009 in patients with relapsed or refractory acute myeloid leukemia (AML) and relapsed or refractory high-risk myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter